Fetal polymorphisms at the ABCB1-transporter gene locus are associated with susceptibility to non-syndromic oral cleft malformations

European Journal of Human Genetics

Volumn 21, Issue 12, 2013, Pages 1436-1441

  Omoumi, Ardeshir ^a   Wang, Zihua ^a,b   Yeow, Vincent ^c   Wu Chou, Yah Huei ^d   Chen, Philip K ^d   Ruczinski, Ingo ^e   Cheng, Joanne ^c   Cheah, Felicia S H ^a   Lee, Caroline G ^a,b,f   Beaty, Terri H ^e   Chong, Samuel S ^a,g  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^g NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

ATP binding cassette transporters; cleft lip; cleft palate; disease susceptibility; placenta; single nucleotide polymorphism

Indexed keywords

ABCB1 GENE; ABCC1 GENE; ABCC2 GENE; ABCG2 GENE; ALLELE; ARTICLE; CONTROLLED STUDY; GENE; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MOUTH MALFORMATION; NON SYNDROMIC ORAL CLEFT; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; UMBILICAL CORD BLOOD;

ALLELES; CASE-CONTROL STUDIES; CLEFT LIP; CLEFT PALATE; FETUS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INFANT, NEWBORN; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; SINGAPORE; TAIWAN;

EID: 84887621040     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2013.25     Document Type: Article

References (43)

1. Gupta RC, Sastry BV: Toxicology of the Placenta, in General and Applied Toxicology, (eds Ballantyne B, Marrs T, Syversen T) 1233-1263 (Grove's Dictionaries, Inc: New York, 2000).
2. St-Pierre MV, Serrano MA, Macias RI et al: Expression of members of the multidrug resistance protein family in human term placenta. Am J Physiol Regul Integr Comp Physiol 2000; 279: R1495-R1503.
3. Derijcke A, Eerens A, Carels C: The incidence of oral clefts: a review. Br J Oral Maxillofac Surg 1996; 34: 488-494.
4. Cooper Me, Ratay JS, Marazita ML: Asian oral-facial cleft birth prevalence. Cleft Palate Craniofac J 2006; 43: 580-589.
5. Jugessur A, Murray JC: Orofacial clefting: recent insights into a complex trait. Curr Opin Genet Dev 2005; 15: 270-278.
6. Arpino C, Brescianini S, Robert E et al: Teratogenic effects of antiepileptic drugs: use of an International Database on Malformations and Drug Exposure (MADRE). Epilepsia 2000; 41: 1436-1443.
7. Little J, Cardy A, Munger RG: Tobacco smoking and oral clefts: a meta-analysis. Bull World Health Organ 2004; 82: 213-218.
8. Lorente C, Cordier S, Goujard J et al: Tobacco and alcohol use during pregnancy and risk of oral clefts. Occupational Exposure and Congenital Malformation Working Group. Am J Public Health 2000; 90: 415-419.
9. Natsume N, Kawai T, Ogi N, Yoshida W: Maternal risk factors in cleft lip and palate: case control study. Br J Oral Maxillofac Surg 2000; 38: 23-25.
10. Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA: Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000; 343: 1608-1614.
11. Laird NM, Lange C: Family-based designs in the age of large-scale gene-association studies. Nat Rev Genet 2006; 7: 385-394.
12. Gauderman WJ: Sample size requirements for matched case-control studies of geneenvironment interaction. Stat Med 2002; 21: 35-50.
13. Kim RB, Leake BF, Choo EF et al: Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70: 189-199.
14. Tang K, Ngoi SM, Gwee PC et al: Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 2002; 12: 437-450.
15. Sham PC, Curtis D: An extended transmission/disequilibrium test (TDT) for multi-allele marker loci. Ann Hum Genet 1995; 59: 323-336.
16. Kazeem GR, Farrall M: Integrating case-control and TDT studies. Ann Hum Genet 2005; 69: 329-335.
17. Gil S, Saura R, Forestier F, Farinotti R: P-glycoprotein expression of the human placenta during pregnancy. Placenta 2005; 26: 268-270.
18. Mathias AA, Hitti J, Unadkat JD: P-glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages. Am J Physiol Regul Integr Comp Physiol 2005; 289: R963-R969.
19. Sun M, Kingdom J, Baczyk D, Lye SJ, Matthews SG, Gibb W: Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation. Placenta 2006; 27: 602-609.
20. Mao Q: BCRP/ABCG2 in the placenta: expression, function and regulation. Pharm Res 2008; 25: 1244-1255.
21. Pascolo L, Fernetti C, Pirulli D, Crovella S, Amoroso A, Tiribelli C: Effects of maturation on RNA transcription and protein expression of four MRP genes in human placenta and in BeWo cells. Biochem Biophys Res Commun 2003; 303: 259-265.
22. Meyer zu Schwabedissen HE, Jedlitschky G, Gratz M et al: Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation. Drug Metab Dispos 2005; 33: 896-904.
23. Ceckova-Novotna M, Pavek P, Staud F: P-glycoprotein in the placenta: expression, localization, regulation and function. Reprod Toxicol 2006; 22: 400-410.
24. Kolwankar D, Glover DD, Ware JA, Tracy TS: Expression and function of ABCB1 and ABCG2 in human placental tissue. Drug Metab Dispos 2005; 33: 524-529.
25. Lankas GR, Wise LD, Cartwright ME, Pippert T, Umbenhauer DR: Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod Toxicol 1998; 12: 457-463.
26. Smit JW, Huisman MT, van Tellingen O, Wiltshire HR, Schinkel AH: Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Invest 1999; 104: 1441-1447.
27. Hitzl M, Schaeffeler E, Hocher B et al: Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1). Pharmacogenetics 2004; 14: 309-318.
28. Sherif A-R, Tatiana N, Gary DVH, Mahmoud A: Effect of the G2677A/T polymorphism in the multidrug resistance 1 gene (MDR1, ABCB1) on P-glycoprotein (P-gp) expression in human placenta. Am J Obs Gyn 2007; 197: S172.
29. Tanabe M, Ieiri I, Nagata N et al: Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001; 297: 1137-1143.
30. Haenisch S, Zimmermann U, Dazert E et al: Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J 2007; 7: 56-65.
31. Meissner K, Jedlitschky G, Meyer zu Schwabedissen H et al: Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary polymorphisms. Pharmacogenetics 2004; 14: 381-385.
32. Jeong H, Herskowitz I, Kroetz DL, Rine J: Function-altering SNPs in the human multidrug transporter gene ABCB1 identified using a Saccharomyces-based assay. PLoS Genet 2007; 3: e39.
33. Aird RE, Thomson M, Macpherson JS, Thurston DE, Jodrell DI, Guichard SM: ABCB1 genetic polymorphism influences the pharmacology of the new pyrrolobenzodiazepine derivative SJG-136. Pharmacogenomics J 2008; 8: 289-296.
34. Vaclavikova R, Nordgard SH, Alnaes GI et al: Single nucleotide polymorphisms in the multidrug resistance gene 1 (ABCB1): effects on its expression and clinicopathological characteristics in breast cancer patients. Pharmacogenet Genomics 2008; 18: 263-273.
35. Abu-Qare Aw, Elmasry E, Abou-Donia MB: A role for P-glycoprotein in environmental toxicology. J Toxicol Environ Health B Crit Rev 2003; 6: 279-288.
36. Mathijssen RH, Marsh S, Karlsson MO et al: Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 2003; 9: 3246-3253.
37. Kimchi-Sarfaty C, Oh JM, Kim IW et al: A 'silent' polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315: 525-528.
38. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W: Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C4T affects mRNA stability. Pharmacogenet Genomics 2005; 15: 693-704.
39. Wang Z, Wang J, Tantoso E et al: Signatures of recent positive selection at the ATPbinding cassette drug transporter superfamily gene loci. Hum Mol Genet 2007a; 16: 1367-1380.
40. Mizuarai S, Aozasa N, Kotani H: Single nucleotide polymorphisms result in impaired membrane localization and reduced ATPase activity in multidrug transporter ABCG2. Int J Cancer 2004; 109: 238-246.
41. Kobayashi D, Ieiri I, Hirota T et al: Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos 2005; 33: 94-101.
42. Tamura A, Wakabayashi K, Onishi Y et al: Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2. Cancer Sci 2007; 98: 231-239.
43. Yeo GW, Van Nostrand EL, Liang TY: Discovery and analysis of evolutionarily conserved intronic splicing regulatory elements. PLoS Genet 2007; 3: e85.